ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
2023年5月2日 - 2:00PM
Ad hoc announcement pursuant to Art. 53 LR of the
SIX Swiss Exchange
GENEVA, Switzerland –
May 2,
2023 – ObsEva SA
(SIX: OBSN), a
biopharmaceutical company developing novel therapies for women’s
health, today announced that Fabien de Ladonchamps has been
appointed Chief Executive Officer effective May 1, 2023. Mr. de
Ladonchamps succeeds Will Brown who previously held the position of
Interim Chief Executive Officer and Chief Financial Officer. Mr.
Brown, who leaves his functions and the Executive Committee with
immediate effect, will serve as a strategic advisor to the Company
for the following six months to aid in the transition.
“I’m very pleased to see Fabien taking over the
Chief Executive Officer responsibility, and with his appointment
our plans to consolidate operations in Switzerland are now
completed. I know Fabien’s excellent financial and strategic
expertise will serve ObsEva well," commented Dr. Ernest Loumaye,
MD, PhD, Interim Chairman of the Board of Directors of ObsEva. “On
behalf of the Board, I would like to warmly thank Will for his
service to ObsEva in leading the restructuring efforts over the
last year and wish him all the best in his future endeavors.”
“It is a privilege to become ObsEva’s Chief
Executive Officer, following nearly a decade of service to the
Company, and I am grateful to the Board of Directors for their
trust.” said Fabien de Ladonchamps, Chief Executive Officer. “We
believe nolasiban represents a unique opportunity to advance the
field of infertility, which affects many people worldwide. I look
forward to the next steps of the nolasiban clinical program, as
well as exploring new strategic opportunities.”
Mr. de Ladonchamps is a biotech executive with
25 years of experience in finance and administrative roles,
primarily with Swiss biotech companies. He was a member of ObsEva’s
Executive Committee from October 2013 to July 2022, during which he
had held the roles of Chief Administrative Officer and Interim
Chief Financial Officer. He also served as the sole finance and
accounting officer for the Company for a total of four years during
which over $110 Million in equity proceeds were raised through
private and public financings. Mr. de Ladonchamps was instrumental
in the Company’s listings on both Nasdaq in 2017 and the Swiss
Exchange in 2018. Prior to joining ObsEva, Mr. de Ladonchamps held
a variety of management roles at Addex Therapeutics, from 2008 to
2013. Mr. de Ladonchamps holds a degree in Finance and Accounting
from the Lyon III University in Lyon, France.
About NolasibanNolasiban is a
novel, oral oxytocin receptor antagonist being developed to improve
clinical pregnancy and live birth rates in women undergoing embryo
transfer following in vitro fertilization. ObsEva retains
worldwide, exclusive, commercial rights for nolasiban, except for
the People’s Republic of China where it has been sub-licensed to
Yuyuan.
About ObsEvaObsEva is a
biopharmaceutical company developing novel therapies to improve
women’s reproductive health and pregnancy. ObsEva has established a
development program focused on improving in vitro fertilization
success rates. ObsEva is listed on the SIX Swiss Exchange where it
is traded under the ticker symbol “OBSN”. For more information,
please visit www.ObsEva.com
Disclaimer / Forward
Looking StatementsAny statements contained in this press
release that do not describe historical facts may constitute
forward-looking statements. These statements may be identified by
words such as “believe”, “expect”, “may”, “plan”, “potential”,
“will”, and similar expressions, and are based on ObsEva’s current
beliefs and expectations. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those reflected in such statements. Any forward-looking
statements speak only as of the date of this press release and are
based on information available to ObsEva as of the date of this
release, and ObsEva assumes no obligation to, and does not intend
to, update any forward-looking statements, whether as a result of
new information, future events or otherwise.
For further information, please
contact:
CEO Administrative
ContactShauna
Dillonshauna.dillon@obseva.ch+41 (0) 22 552 1550
Investor
ContactFabien de Ladonchamps,
CEOfabien.deladonchamps@obseva.ch+41 (0) 22 552 1550
###
- ObsEva - Press Release Change in Management_May 2023_Pdf
ObsEva (NASDAQ:OBSV)
過去 株価チャート
から 11 2024 まで 12 2024
ObsEva (NASDAQ:OBSV)
過去 株価チャート
から 12 2023 まで 12 2024